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SUPPLEMENTARY NOTES
ABSTRACT
Metastasis is still a major cause of morbidity and mortality in breast cancer patients. However, current therapy still fails to kill migrating (metastasizing) breast cancer cells. CXCR4 is a chemokine receptor implicated in the metastatic migration of breast cancer cells and its expression predicts poor prognosis in breast cancer patients. Several studies have revealed that the block of CXCR4 functions prevented metastasis in breast cancer. However, CXCR4 is expressed on the surface of several tissues and there are some concerns about using drugs to target CXCR4. In fact, AMD-3100, a CXCR4 receptor blocker, exerted unfavorable side effects in a clinical trial. Therefore, it is necessary to develop tissue-specific and tumorspecific CXCR4 blockers. Because Csk Homologous kinase (CHK) is a negative regulator of CXCR4 and preferentially expressed in breast cancer cells, modulating CHK activity may facilitate the development of side-effect-free treatment for metastatic breast cancer. Our aim is to identify the functional role of CHK in breast cancer metastasis using in vivo xenograft model systems. With resulting information from this study, we may devise treatments that selectively target metastatic breast cancer cells.
SUBJECT TERMS
Breast Cancer Metastasis, CSK homologous kinase, CXCR4 Taken together, CXCR4/CXCL12 signaling axis is a major driving force behind the metastatic migration of breast cancer cells and might be an attractive target for future therapy for metastatic breast cancer. However, CXCR4 is expressed on the surface of several tissues and there have been some concerns about using drugs to target CXCR4. Non-tissue specific blocking of CXCR4 deficieint mice displayed serious heart and artery problems suggesting that antagonizing the signalling activity of CXCR4 might have severe side effects in vivo (6) . In fact, AMD-3100, a CXCR4 receptor blocker, exerted unfavorable side effects in the clinical trial developing gastrointestinal side effects, thrombocytopenia, and atrial and ventricular arrhythmias and the study was stopped (7) . Accordingly, the CXCR4 blockers are not allowed to be used in the clinical practice and the drug is not likely to move forward in its current formulation. Therefore, it is necessary to develop a strategy to interfere CXCR4/CXCL12 signaling axis selectively in target tissues, such as cancer cells.
Csk homologous kinase(CHK) and CXCR4
Activation and dysregulation of signaling pathways often leads to tumorigenesis. Of signaling pathways, protein tyrosine kinase activity is closely associated with tumor progression and CHK has been suggested to play a specific role as a novel negative growth regulator of human breast cancer on the basis of the following observations: 1) Unlike Csk, which is ubiquitously expressed, CHK is specifically expressed in primary breast cancer specimens, but not in normal breast tissues (10) (11) (12) . 2) Unlike Csk, which cannot associate with ErbB-2, CHK binds directly to phosphoTyr1248 of the ErbB-2/neu receptor kinase upon heregulin stimulation and inhibits Src kinase activity 
b. Transplant wtCHK-and dkCHK-transduced breast cancer cells into female NOD/SCID mice
Thirty nine NOD/SCID IL-2γ null mice are needed as recipients. NOD/SCID IL-2γ null mice were bred in our own animal facility and we now maintain them in sufficient numbers to perform the xenotransplantation. During t he e xtension pe riod, w ild-type a nd m utant C HK-transduced S KBR-3 cells will be expanded. Once C HKs-transduced cel ls (from T ask 1 a) are expanded into t he l arge number of cells required for transplantation, we will transplant these cells into NOD/SCID IL-2γ null mice by tail vein injection. 
YY1
We have optimized gel shift assay conditions. During the extension period, we will investigate whether YY1 bi nding t o t he C XCR4 pr omoter is a ssociated w ith th e C HK-mediated C XCR4 r egulation. For this purpose, we will perform gel mobility shift assay. 
Reportable Outcomes
There are no reportable outcomes yet because the experiments are still ongoing. We anticipate to publish one or two manuscripts depend on the results obtained during the NCE period.
Conclusion
CHK showed its ability to regulate CXCR4 mRNA, supporting our hypothesis that CHK signaling axis regulates the metastatic migration o f b reast cancer cells. E specially, wild-type S H2 dom ain, S H2-R147A and SH2-G129A displayed their differential capacity to regulate CXCR4 expression in breast cancer cells. Their small size may allow for improved penetration into breast tumor tissue, although the further xenotransplantation experiments using the mutated CHK expressing breast cancer cell lines are necessary to verify the validity.
